Physician profile
Craig Metroka
NPI 1194848176
$4,264.50
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,432 · 2020: $1,116 · 2021: $716.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,129.65 | 2019-2021 | |
| Janssen Biotech, INC. | $924.51 | 2019-2021 | |
| Viiv Healthcare Company | $802.57 | 2019-2021 | |
| Janssen Products, Lp | $639.91 | 2019-2021 | |
| Abbvie INC. | $258.75 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $239.31 | 2019-2020 | |
| Pfizer INC. | $77.45 | 2019-2020 | |
| Napo Pharmaceuticals INC | $61.23 | 2019 | |
| Janssen Scientific Affairs, LLC | $35.64 | 2019 | |
| Glaxosmithkline, LLC. | $32.88 | 2019 | |
| Lilly USA, LLC | $24.56 | 2019 | |
| Theratechnologies INC. | $22.17 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $15.87 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Metroka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.